Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects

The subtilisin-like proprotein convertases PC1/3 (SPC3) and PC2 (SPC2) are believed to be the major endoproteolytic processing enzymes of the regulated secretory pathway. They are expressed together or separately in neuroendocrine cells throughout the brain and dispersed endocrine system in both vertebrates and invertebrates. Disruption of the gene-encoding mouse PC1/3 has now been accomplished and results in a syndrome of severe postnatal growth impairment and multiple defects in processing many hormone precursors, including hypothalamic growth hormone-releasing hormone (GHRH), pituitary proopiomelanocortin to adrenocorticotropic hormone, islet proinsulin to insulin and intestinal proglucagon to glucagon-like peptide-1 and -2. Mice lacking PC1/3 are normal at birth, but fail to grow normally and are about 60% of normal size at 10 weeks. They lack mature GHRH, have low pituitary growth hormone (GH) and hepatic insulin-like growth factor-1 mRNA levels and resemble phenotypically the “little” mouse (Gaylinn, B. D., Dealmeida, V. I., Lyons, C. E., Jr., Wu, K. C., Mayo, K. E. & Thorner, M. O. (1999) Endocrinology 140, 5066–5074) that has a mutant GHRH receptor. Despite a severe defect in pituitary proopiomelanocortin processing to mature adrenocorticotropic hormone, blood corticosterone levels are essentially normal. There is marked hyperproinsulinemia but without impairment of glucose tolerance. In contrast, PC2-null mice lack mature glucagon and are chronically hypoglycemic (Furuta, M., Yano, H., Zhou, A., Rouille, Y., Holst, J., Carroll, R., Ravazzola, M., Orci, L., Furuta, H. & Steiner, D. (1997) Proc. Natl. Acad. Sci. USA 94, 6646–6651). The PC1/3-null mice differ from a human subject reported with compound heterozygosity for defects in this gene, who was of normal stature but markedly obese from early life. The PC1/3-null mice are not obese. The basis for these phenotypic differences is an interesting topic for further study. These findings prove the importance of PC1/3 as a key neuroendocrine convertase.

[1]  L. Orci,et al.  Severe Defect in Proglucagon Processing in Islet A-cells of Prohormone Convertase 2 Null Mice* , 2001, The Journal of Biological Chemistry.

[2]  N. Seidah,et al.  Gene organization of the mouse pro-hormone and pro-protein convertase PC1. , 1994, DNA and cell biology.

[3]  L. Orci,et al.  Incomplete Processing of Proinsulin to Insulin Accompanied by Elevation of Des-31,32 Proinsulin Intermediates in Islets of Mice Lacking Active PC2* , 1998, The Journal of Biological Chemistry.

[4]  E. Simpson,et al.  Impaired fertility in mice deficient for the testicular germ-cell protease PC4. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Mains,et al.  The prohormone convertases PC1 and PC2 mediate distinct endoproteolytic cleavages in a strict temporal order during proopiomelanocortin biosynthetic processing. , 1993, The Journal of biological chemistry.

[6]  T. Watanabe,et al.  Consensus sequence for precursor processing at mono-arginyl sites. Evidence for the involvement of a Kex2-like endoprotease in precursor cleavages at both dibasic and mono-arginyl sites. , 1992, The Journal of biological chemistry.

[7]  N. Seidah,et al.  The isoforms of proprotein convertase PC5 are sorted to different subcellular compartments , 1996, The Journal of cell biology.

[8]  A. Viale,et al.  Cellular Localization and Role of Prohormone Convertases in the Processing of Pro-melanin Concentrating Hormone in Mammals* , 1999, The Journal of Biological Chemistry.

[9]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[10]  S. O’Rahilly,et al.  Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene , 1997, Nature Genetics.

[11]  D. Steiner,et al.  Specificity of Prohormone Convertase 2 on Proenkephalin and Proenkephalin-related Substrates* , 1998, The Journal of Biological Chemistry.

[12]  D. Constam,et al.  Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. , 1998, Development.

[13]  L. Orci,et al.  Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Steiner,et al.  Differential Processing of Proglucagon by the Subtilisin-like Prohormone Convertases PC2 and PC3 to Generate either Glucagon or Glucagon-like Peptide (*) , 1995, The Journal of Biological Chemistry.

[15]  S. Shoelson,et al.  Preferential cleavage of des-31,32-proinsulin over intact proinsulin by the insulin secretory granule type II endopeptidase. Implication of a favored route for prohormone processing. , 1992, The Journal of biological chemistry.

[16]  L. Orci,et al.  Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Muller,et al.  The cell biology of the prohormone convertases PC1 and PC2. , 1999, Progress in nucleic acid research and molecular biology.

[18]  A. Joyner,et al.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.

[19]  I. Lindberg,et al.  Prodynorphin Processing by Proprotein Convertase 2 , 1998, The Journal of Biological Chemistry.

[20]  E. Nillni,et al.  Posttranslational Processing of Progrowth Hormone-Releasing Hormone1. , 1999, Endocrinology.

[21]  An Zhou,et al.  Proteolytic Processing in the Secretory Pathway* , 1999, The Journal of Biological Chemistry.

[22]  P. Leder,et al.  The Neuroendocrine Protein 7B2 Is Required for Peptide Hormone Processing In Vivo and Provides a Novel Mechanism for Pituitary Cushing’s Disease , 1999, Cell.

[23]  E. Eicher,et al.  Stimulation of growth in the little mouse. , 1976, The Journal of endocrinology.

[24]  A. Arimura,et al.  Prohormone Convertase PC4 Processes the Precursor of PACAP in the Testis , 2000, Annals of the New York Academy of Sciences.

[25]  N. Miki,et al.  Hypothalamic growth hormone-releasing factor (GRF) participates in the negative feedback regulation of growth hormone secretion. , 1989, Life sciences.

[26]  A. Grüters,et al.  Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans , 1998, Nature Genetics.

[27]  D. Steiner,et al.  Mortality in 7B2 null mice can be rescued by adrenalectomy: Involvement of dopamine in ACTH hypersecretion , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Polonskaia,et al.  Defective Prodynorphin Processing in Mice Lacking Prohormone Convertase PC2 , 2000, Journal of neurochemistry.

[29]  D. Drucker Glucagon-like peptide 2. , 1997, The Journal of clinical endocrinology and metabolism.

[30]  J. Dixon,et al.  Purification and characterization of the candidate prohormone-processing enzyme SPC3 produced in a mouse L cell line. , 1993, The Journal of biological chemistry.

[31]  Aldons J. Lusis,et al.  Molecular basis of the little mouse phenotype and Implications for cell type-specific growth , 1993, Nature.

[32]  J. Holst,et al.  Structure, measurement, and secretion of human glucagon-like peptide-2 , 2000, Peptides.

[33]  M. Thorner,et al.  The Mutant Growth Hormone-Releasing Hormone (GHRH) Receptor of the Little Mouse Does Not Bind GHRH1. , 1999, Endocrinology.

[34]  M. Ono,et al.  Characterization and Localization of Mouse Hypothalamic Growth Hormone‐Releasing Factor and Effect of Gold Thioglucose‐Induced Hypothalamic Lesions , 1994, Journal of neuroendocrinology.

[35]  J. Holst,et al.  Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet , 1996, Diabetes Care.

[36]  P. Halban,et al.  Role of the Prohormone Convertase PC3 in the Processing of Proglucagon to Glucagon-like Peptide 1* , 1997, The Journal of Biological Chemistry.

[37]  D. Constam,et al.  SPC4/PACE4 regulates a TGFbeta signaling network during axis formation. , 2000, Genes & development.

[38]  P. Kitabgi,et al.  Evidence That PC2 Is the Endogenous Pro-neurotensin Convertase in rMTC 6-23 Cells and That PC1- and PC2-transfected PC12 Cells Differentially Process Pro-neurotensin (*) , 1996, The Journal of Biological Chemistry.

[39]  J. Holst,et al.  1 - Assays for Peptide Products of Somatostatin Gene Expression , 1991 .

[40]  S. O’Rahilly,et al.  Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. , 1995, The New England journal of medicine.

[41]  D. Drucker,et al.  Gut adaptation and the glucagon-like peptides , 2002, Gut.

[42]  R. Palmiter,et al.  Dwarf mice produced by genetic ablation of growth hormone-expressing cells. , 1988, Genes & development.

[43]  S. Suhr,et al.  Growth hormone-releasing hormone: synthesis and signaling. , 1995, Recent progress in hormone research.

[44]  P. Mullis,et al.  Decreased expression of the GHRH receptor gene due to a mutation in a Pit-1 binding site. , 2002, Molecular endocrinology.